What drove the company's revenue growth in FY26?

Growth came from the oncology and biopharmaceuticals businesses. The oncology segment alone contributed over ₹16 billion.

How did the dividend payout change?

The board recommended a final dividend of ₹36 per share. This is an increase from the ₹32 per share paid in the prior year.

Are there any changes to the audit team?

The company plans to appoint BSR & Co as its new statutory auditors. This is subject to shareholder approval.

What was the net profit for the year?

Net profit rose to ₹1.9 billion. This is an increase from the ₹1.2 billion reported in the previous year.

Earnings · Pharmaceuticals · Large cap

AstraZeneca Pharma India profit rises to ₹1.9 billion

Revenue hit ₹22.8 billion for FY26 as oncology sales grew. The board recommended a final dividend of ₹36 per share.

— 1 earlier story on Astrazeneca Pharma India Ltd. →

ASTRAZEN 26 May 2026 · 7:17 PM IST Verify on BSE · NSE

Mkt cap₹22,406 cr

P/E111.53×

ROE15.02%

Debt / eq.0.00

Div yld0.36%

₹1.9 billion Net profit for FY26, up from ₹1.2 billion in the prior year.

What's new

Revenue reached ₹22.8 billion, a 33% increase over the previous year.
Oncology segment revenue exceeded ₹16 billion.
The board recommended a final dividend of ₹36 per share.

Why this matters

The company is successfully scaling its high-margin oncology franchise. Profit growth of 62% significantly outpaced revenue growth of 33%.

What we're watching

Shareholder approval for the appointment of BSR & Co as statutory auditors.
Continued sales performance of Durvalumab and Osimertinib.
The next test is sustaining these margins.

The full read

AstraZeneca Pharma India grew revenue to ₹22.8 billion for the financial year ended March 2026. This represents a 33% increase from the previous year, with the oncology business providing over ₹16 billion of that total. Profit rose to ₹1.9 billion from ₹1.2 billion.

Growth is accelerating.

New indications for Durvalumab and Osimertinib helped the company reach these results, while the board recommended a final dividend of ₹36 per share, up from ₹32 per share, and the company plans to appoint BSR & Co as its new statutory auditors, pending shareholder approval. The next test is whether the company can maintain this pace of expansion in the coming year.

Questions answered

What drove the company's revenue growth in FY26?: Growth came from the oncology and biopharmaceuticals businesses. The oncology segment alone contributed over ₹16 billion.
How did the dividend payout change?: The board recommended a final dividend of ₹36 per share. This is an increase from the ₹32 per share paid in the prior year.
Are there any changes to the audit team?: The company plans to appoint BSR & Co as its new statutory auditors. This is subject to shareholder approval.
What was the net profit for the year?: Net profit rose to ₹1.9 billion. This is an increase from the ₹1.2 billion reported in the previous year.

Mentioned: AstraZeneca Pharma India · Price Waterhouse & Co · BSR & Co

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on ASTRAZEN →

26 May 2026 · 7:17 PM IST AstraZeneca Pharma India profit rises to ₹1.9 billion
5d ago AstraZeneca India wins CDSCO nod for Calquence in MCL